Literature DB >> 25154010

Methamphetamine self-administration in humans during D-amphetamine maintenance.

Erika Pike1, William W Stoops, Lon R Hays, Paul E A Glaser, Craig R Rush.   

Abstract

Agonist replacement may be a viable treatment approach for managing stimulant use disorders. This study sought to determine the effects of D-amphetamine maintenance on methamphetamine self-administration in stimulant using human participants. We predicted that D-amphetamine maintenance would reduce methamphetamine self-administration. Eight participants completed the protocol, which tested 2 D-amphetamine maintenance conditions in counterbalanced order (0 and 40 mg/d). Participants completed 4 experimental sessions under each maintenance condition in which they first sampled 1 of 4 doses of intranasal methamphetamine (0, 10, 20, or 30 mg). Participants then had the opportunity to respond on a computerized progressive-ratio task to earn portions of the sampled methamphetamine dose. Subject-rated drug effect and physiological measures were completed at regular intervals prior to and after sampling methamphetamine. Methamphetamine was self-administered as an orderly function of dose regardless of the maintenance condition. Methamphetamine produced prototypical subject-rated effects on 12 items of the drug-effects questionnaires, 8 of which were attenuated by D-amphetamine maintenance (eg, increased ratings were attenuated on items such as Any Effect, Like Drug, and Willing to Take Again on the Drug Effect Questionnaire). Methamphetamine produced significant increases in systolic blood pressure, which were attenuated by D-amphetamine maintenance compared to placebo maintenance. Methamphetamine was well tolerated during D-amphetamine maintenance and no adverse events occurred. Although D-amphetamine attenuated some subject-rated effects of methamphetamine, the self-administration results are concordant with those of clinical trials showing that D-amphetamine did not reduce methamphetamine use. Unique pharmacological approaches may be needed for treating amphetamine use disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25154010      PMCID: PMC4239155          DOI: 10.1097/JCP.0000000000000207

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  35 in total

1.  Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART).

Authors:  C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown
Journal:  J Exp Psychol Appl       Date:  2002-06

Review 2.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

Review 3.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

Review 4.  Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies.

Authors:  David V Herin; Craig R Rush; John Grabowski
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

5.  Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance.

Authors:  Joshua A Lile; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2011-07-06       Impact factor: 4.492

6.  Attentional bias in emotional disorders.

Authors:  C MacLeod; A Mathews; P Tata
Journal:  J Abnorm Psychol       Date:  1986-02

7.  Methamphetamine self-administration by humans.

Authors:  C L Hart; A S Ward; M Haney; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

8.  Self-administration of cocaine by humans: choice between smoked and intravenous cocaine.

Authors:  R W Foltin; M W Fischman
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

Review 9.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

Review 10.  Agonist replacement for stimulant dependence: a review of clinical research.

Authors:  William W Stoops; Craig R Rush
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more
  9 in total

1.  Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys.

Authors:  Kathryn L Schwienteck; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2015-09-02       Impact factor: 4.492

Review 2.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

3.  Agmatine attenuates the discriminative stimulus and hyperthermic effects of methamphetamine in male rats.

Authors:  David A Thorn; Jiuzhou Li; Yanyan Qiu; Jun-Xu Li
Journal:  Behav Pharmacol       Date:  2016-09       Impact factor: 2.293

Review 4.  Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.

Authors:  Matthew L Banks
Journal:  Ann N Y Acad Sci       Date:  2016-12-09       Impact factor: 5.691

5.  Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Authors:  Erika Pike; William W Stoops; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

6.  Effects of the GluN2B-selective antagonist Ro 63-1908 on acquisition and expression of methamphetamine conditioned place preference in male and female rats.

Authors:  Justin R Yates; Hunter L Campbell; Lauren L Hawley; Matthew J Horchar; Joy L Kappesser; Makayla R Wright
Journal:  Drug Alcohol Depend       Date:  2021-05-26       Impact factor: 4.852

7.  The Body Mass Index, Blood Pressure, and Fasting Blood Glucose in Patients With Methamphetamine Dependence.

Authors:  Dezhao Lv; Meijuan Zhang; Xuru Jin; Jiyun Zhao; Bin Han; Hang Su; Jie Zhang; Xiangyang Zhang; Wenwei Ren; Jincai He
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Effects of Methamphetamine on Testes Histopathology and Spermatogenesis Indices of Adult Male Rats.

Authors:  Arezoo Saberi; Gholamreza Sepehri; Zohreh Safi; Behzad Razavi; Faranak Jahandari; Kouros Divsalar; Ehsan Salarkia
Journal:  Addict Health       Date:  2017

Review 9.  A mechanistic overview of approaches for the treatment of psychostimulant dependence.

Authors:  Kathrine Louise Jensen; Søren Brøgger Jensen; Kenneth Lindegaard Madsen
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.